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Introduction: Previously published results from a randomized
phase III study of pemetrexed plus cisplatin in patients with malig-
nant pleural mesothelioma (MPM) demonstrated a significant sur-
vival benefit and higher response rate compared with cisplatin.
Although pemetrexed was under review by regulatory agencies, an
International Expanded Access Program (EAP) provided more than
3000 mesothelioma patients with access to single-agent pemetrexed
or pemetrexed in combination with cisplatin or carboplatin in 13
countries. This manuscript reports the safety and efficacy data from
the nonrandomized open-label study in chemonaı¨ve patients receiv-
ing pemetrexed plus platinum under the EAP.
Methods: Patients with histologically confirmed MPM, not amena-
ble to curative surgery, received pemetrexed 500 mg/m2 in combi-
nation with either cisplatin 75 mg/m2 or carboplatin AUC 5, once
every 21 days with standard premedication. Efficacy data were
recorded at the end of study participation.
Results: A total of 1704 chemonaı¨ve patients received pemetrexed
plus cisplatin (n  843) or pemetrexed plus carboplatin (n  861)
and were evaluated for safety. The efficacy evaluable population
consisted of 745 patients in the pemetrexed plus cisplatin group and
752 patients in the pemetrexed plus carboplatin group for whom
physician-reported tumor response was available. The pemetrexed
plus cisplatin group demonstrated a response rate of 26.3% com-
pared with 21.7% for the pemetrexed plus carboplatin group, with
similar 1-year survival rates (63.1% versus 64.0%) and median time
to progressive disease (7 months versus 6.9 months). The most
common grade 3/4 hematologic toxicity was neutropenia in 23.9%
of the pemetrexed plus cisplatin group and 36.1% of the pemetrexed
plus carboplatin group.
Conclusion: This large EAP confirmed the activity of pemetrexed
plus cisplatin and pemetrexed plus carboplatin in chemonaı¨ve pa-
tients with MPM, demonstrating clinically similar time to progres-
sive disease and 1-year survival rates.
Key Words: Cisplatin, Carboplatin, Expanded access program,
Malignant pleural mesothelioma, Pemetrexed.
(J Thorac Oncol. 2008;3: 756–763)
Malignant pleural mesothelioma (MPM) is a life-threat-ening malignancy with an incidence that is increasing
worldwide. Projections from Europe indicate a doubling of
the number of new cases, from 5,000 in 1998 to an estimated
9,000 in 2018.1 Recent estimates for the population-based
incidence of MPM is 1.1 per 100,000 in Germany and 1.25
per 100,000 in the United Kingdom, and this rate is expected
to double in the next two decades.2
In a phase I clinical and pharmacokinetic study, the
combination of pemetrexed and cisplatin has shown antitu-
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mor activity in different tumor types, including patients with
MPM,3 and the recommended dose was 500 mg/m2 plus
cisplatin 75 mg/m2. In a large, phase III, randomized trial
using the same dose, pemetrexed yielded a response rate of
41.3% in combination with cisplatin and a prolonged survival
time when compared with single-agent cisplatin (12.1 versus
9.3 months).4 The combination of pemetrexed and cisplatin,
which has emerged as the most effective chemotherapeutic
regimen in MPM, is associated with higher response rates and
improved survival and quality of life.4 This combination has
been approved by the United States Food and Drug Admin-
istration5 and the European regulatory agency [The European
Medicines Agency/Committee for Medicinal Products for
Human Use] as a first-line chemotherapy regimen in MPM.
The first compassionate-use program for pemetrexed
was started in the United States. Combination therapy with
pemetrexed and cisplatin under the Expanded Access Pro-
gram (EAP) was evaluated in both chemonaı¨ve and pretreated
patients. In this large U S EAP, chemonaı¨ve patients with
MPM who were treated with pemetrexed in combination with
cisplatin experienced an overall response rate of 20.5% and a
median survival of 10.8 months.6
Carboplatin, a better tolerated and easier to deliver
analog of cisplatin, has also demonstrated activity in me-
sothelioma when used as a single agent (with response rates
of 7–16%), and is less nephrotoxic.7,8 In phase I and II trials,
carboplatin combined with pemetrexed showed higher re-
sponse rates, from 18.6 to 32%, and median survival times of
13 to 15 months in patients with MPM.9,10
A second EAP for pemetrexed in mesothelioma was
started for the benefit of patients in other countries. This
International EAP for pemetrexed enrolled patients in 13
countries. The primary objective was to provide mesotheli-
oma patients with access to pemetrexed; secondary objectives
included basic safety data collection, determination of best
tumor response, time to progressive disease (TTPD), and
overall survival. This report presents the findings in che-
monaı¨ve patients with MPM who received pemetrexed in
combination with a platinum analog (cisplatin or carboplatin)
as first-line treatment under the International EAP. Chemona-
ı¨ve patients who received single-agent pemetrexed appeared
to differ in terms of age and performance status and were
therefore not included in the present analysis. Key results for
this patient subgroup were, however, presented by Manegold
et al. in a brief report.11
PATIENTS AND METHODS
Patients
Patients at least 18 years of age with a histologically
proven diagnosis of mesothelioma who were not candidates
for curative surgery were enrolled under this International
EAP. Informed consent was obtained before enrollment.
Patients had to be clinically staged using the International
Mesothelioma Interest Group Tumor Nodes Metastasis stag-
ing criteria.12 Measurable lesions were not required for en-
rollment. Patients could have been chemonaı¨ve, or may have
received one or more lines of prior chemotherapy for malig-
nant mesothelioma. Patients were required to have a perfor-
mance status70 on the Karnofsky scale (after any palliative
measures, including pleural drainage, had occurred). Patients
were required to have adequate bone marrow reserve [abso-
lute neutrophil count (ANC) 1.5  109/liter, platelets
100  109/liter, and hemoglobin 9 g/dl], hepatic function
[bilirubin 1.5 times the upper limit of normal (ULN),
alkaline phosphatase, aspartate transaminase (AST), and ala-
nine transaminase 3.0  ULN (alkaline phosphatase, AST,
and alanine transaminase 5 ULN if liver had tumor involve-
ment)], and normal renal function (calculated creatinine
clearance 45 ml/min) based on the standard Cockroft and
Gault formula.13 Prior pleurodesis was allowed. Pregnant
women were not eligible, and all men and women of repro-
ductive potential were required to use an approved method of
birth control. Patients with serious concomitant disorders
incompatible with the study were excluded at the investiga-
tor’s decision.
Treatment Plan
Under the International EAP, mesothelioma patients
received one of the three treatment options. The primary
treatment option was pemetrexed plus cisplatin. Patients who
were unable to tolerate the cisplatin regimen received either
pemetrexed plus carboplatin or single-agent pemetrexed. Pa-
tient assignments were nonrandomized and based on individ-
ual investigator decisions that considered the clinical status
and therapy goals of both the patient and physician. In this
report, we describe the findings from 1704 chemonaı¨ve pa-
tients with MPM who received either pemetrexed plus cis-
platin or pemetrexed plus carboplatin.
Pemetrexed Plus Cisplatin Group
Pemetrexed was administered at the dose of 500 mg/m2
as a 10-minute intravenous infusion, diluted in 100 ml normal
saline. Approximately 30 minutes after the administration of
pemetrexed, cisplatin was administered intravenously at 75
mg/m2 over 2 hours. Both drugs were administered on day 1
of a 21-day cycle.
Pemetrexed Plus Carboplatin Group
Pemetrexed was administered at the dose of 500 mg/m2
as a 10-minute intravenous infusion, diluted in 100 ml normal
saline. Approximately 30 minutes after the administration of
pemetrexed, carboplatin AUC 5 was administered intrave-
nously over 30 minutes. Both drugs were administered on day
1 of a 21-day cycle.
Folic acid supplementation, 350 g to 600 g or
equivalent, was given orally daily beginning approximately 1
to 2 weeks prior to the first dose of pemetrexed and continu-
ing daily until at least 3 weeks after the last pemetrexed dose
was given. A vitamin B12 injection, 1000 g, was adminis-
tered intramuscularly approximately 1 to 2 weeks prior to the
first dose of pemetrexed, and was repeated approximately
every 9 weeks until the patient discontinued from the EAP.
Additionally, dexamethasone 4 mg (or an equivalent cortico-
steroid) was given orally twice per day on the day before, the
day of, and the day after each dose of pemetrexed to reduce
the risk of severe skin rash. Study therapy was allowed to
continue until there was evidence of progressive disease, the
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patient experienced unacceptable toxicity, the investigator
decided to discontinue the patient, the patient requested
discontinuation, or if Lilly planned to stop the EAP program
when pemetrexed became commercially available.
Dose Adjustments
Dose adjustments at the start of a subsequent cycle of
therapy were based on platelet and neutrophil nadir (lowest
value) counts from the preceding cycle of therapy (ANC had
to be 1.5  109/liter and platelets 100  109/liter before
the start of any cycle). Dose delays up to 42 days were
permitted for recovery from study-drug toxicity. Upon recov-
ery, treatment was resumed from the preceding cycle of
therapy at 100% of the previous dose for an ANC 0.5 
109/liter and platelets50 109/liter, at 75% of the previous
dose for an ANC 0.5  109/liter and platelets 50 
109/liter, or at 50% of the previous dose for platelets 50 
109/litre. Any patient requiring three dose reductions was
discontinued from the study. In the event of diarrhea requir-
ing hospitalization (or at least grade 3), treatment was de-
layed until diarrhea had resolved before proceeding. Treat-
ment was resumed at 75% of the previous dose level. For
other nonhematologic events greater than or equal to grade 3
(with the exception of grade 3 transaminase elevations),
treatment was delayed until resolution was less than or equal
to the patient’s baseline CTCAE grade before proceeding.
Treatment was resumed at 75% of the previous dose level, if
deemed appropriate by the treating physician.
Efficacy Assessments
Patients’ tumor response was assessed preferably using
the Response Evaluation Criteria in Solid Tumors.14 The
Southwest Oncology Group criteria15 or the World Health
Organization criteria16 were also acceptable for response
evaluation. The best overall response status was determined
when the patient completed or discontinued from the study.
Overall tumor response rate was defined as the number of
patients with documented partial response or complete re-
sponse divided by the number of patients qualified for tumor
response analysis (evaluable patients). TTPD was estimated
in months from the date of the first dose to the date of the first
documentation of progressive disease. Survival status was
collected when the patient completed therapy and at one
follow-up visit 30 days after study completion. Survival time
was estimated in months from the date of the first dose to the
date of death.
Safety Assessments
Safety was assessed by physical examination and clin-
ical laboratory tests. Patients were rated for adverse events
before each cycle using the Common Terminology Criteria
for Adverse Events (CTCAE) scale, version 2.17 However,
only myelosuppression data were collected in the clinical trial
* For 57 patients, the prior treatment status was not known. 
† Of the 2074 chemonaïve patients, 51 patients did not receive treatment. 
‡ Of the 1011 previously treated patients, 23 patients did not receive treatment. 
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FIGURE 1. Patients with pleural mesothelioma who enrolled in the pemetrexed International Expanded Access Program. EAP,
expanded access program; N, sample size; n, number of patients. The highlighted boxes are the patient population described
in detail in this manuscript.
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database. Serious adverse events (SAEs) were reported by the
investigators to the sponsor’s global safety surveillance sys-
tem, and were monitored by the Eli Lilly clinical research
physician.
Statistical Methods
A summary of statistics was provided. Missing data
were not considered in the efficacy or safety analysis. Only
the available data in each cycle were summarized. The
investigator-assessed best overall tumor response was sum-
marized with proportion and 95% confidence intervals (CI).
TTPD and survival time were calculated using Kaplan-Meier
estimates. Patients who discontinued or for whom no obser-
vation was available were censored. The log-rank test was
conducted to compare the treatment groups.
All subjects who received at least one dose of the study
drug were classified as the safety population. All patients who
were in the safety population and who had at least one tumor
response observation after baseline were classified as the
evaluable efficacy population.
RESULTS
Baseline Characteristics and Patient
Disposition
A total of 3142 patients with MPM was entered into the
International EAP; 2074 were chemonaı¨ve and 1011 were
previously treated (Figure 1). The first patient was assigned to
therapy on November 6, 2002 and the last patient completed
therapy on October 19, 2006. The present report focuses on the
subset of 1704 chemonaı¨ve patients who were able to tolerate
combination chemotherapy with either pemetrexed plus cis-
platin or pemetrexed plus carboplatin. Results for other pa-
tient subgroups have been described previously.11,18 Of the
1704 chemonaı¨ve patients, 843 patients received pemetrexed
plus cisplatin and 861 patients received pemetrexed plus
carboplatin and constituted the safety population. Tumor
response data were available for 745 evaluable patients in the
pemetrexed plus cisplatin group and for 752 evaluable pa-
tients in the pemetrexed plus carboplatin group.
The baseline patient demographics and characteristics
are presented in Table 1. In the pemetrexed plus cisplatin
group, the median age was 62 years (range, 24.0–78.0 years),
85.3% of patients were male, 98.9% were Caucasian, and
86.8% of patients had a Karnofsky performance status 80.
In the pemetrexed plus carboplatin group, the median age was
66 years (range, 35.0–89.0 years), 80.5% of patients were
male, 99.9% were Caucasian, and 85.8% of patients had a
Karnofsky performance status 80. Nine patients (1.1%) in
the pemetrexed plus carboplatin group had a performance
status 70, which was a protocol violation.
The main reasons for study discontinuation in the
pemetrexed plus cisplatin group were objective tumor pro-
gression (19.9%), clinical disease progression (5.8%), pa-
tient-physician perception (22.5%), and other (12.6%). The
main reasons for study discontinuation in the pemetrexed plus
carboplatin group were objective tumor progression (20.7%),
patient-physician perception (16.3%), and clinical disease
progression (7.9%). Three patients (0.3%) in the pemetrexed
plus carboplatin group discontinued from the study because
of death from study-drug toxicity.
Treatment
A median of five cycles (range, 1–26 cycles) was
delivered to the patients in the pemetrexed plus cisplatin
group, and a median of six cycles (range, 1–35 cycles) to the
patients in the pemetrexed plus carboplatin group. In the
pemetrexed plus cisplatin group, 405 (48%) patients com-
pleted six cycles of treatment and in the pemetrexed plus
carboplatin group, 452 (52.5%) patients completed six cycles.
At least 47 patients in each group received 10 treatment
cycles, and at least five patients in each group received 20
treatment cycles. The relative dose intensity (the percentage
of dose delivered compared with the planned dose of a drug)
was high for pemetrexed and cisplatin. In the pemetrexed
plus cisplatin group, 95.0 and 94.9% of pemetrexed and
cisplatin doses were delivered unadjusted. The relative dose
intensities were 98.7% and 97.1%, respectively. In the pem-
etrexed plus carboplatin group, 91.3 and 91.2% of pem-
etrexed and carboplatin doses were delivered unadjusted.
Although the relative dose intensity for pemetrexed was
97.1%, the relative dose intensity for carboplatin could not be
calculated because the details regarding the creatinine clear-
ance level were not captured.
TABLE 1. Baseline Demographics and Patient Characteristics
Characteristic
Chemonaïve
Pemetrexed 
Cisplatin
(n  843)
Chemonaïve
Pemetrexed 
Carboplatin
(n  861)
Median age, yr (range) 62.0 (24.0–78.0) 66.0 (35.0–89.0)
Gender, n (%)
Male 719 (85.3) 693 (80.5)
Female 124 (14.7) 168 (19.5)
Ethnic origin, n (%)
Caucasian 834 (98.9) 860 (99.9)
African descent 4 (0.5) 0
Hispanic 3 (0.4) 0
East/southeast 1 (0.1) 0
Western asian 1 (0.1) 0
Other 0 1 (0.1)
Histological diagnosis, n (%)
Epithelial 565 (67.0) 593 (68.9)
Sarcomatoid 53 (6.3) 58 (6.7)
Mixed cells 77 (9.1) 63 (7.3)
Others 148 (17.6) 147 (17.1)
KPS, n (%)*
100 165 (21.6) 153 (19.3)
90 278 (36.3) 252 (31.7)
80 221 (28.9) 276 (34.8)
70 101 (13.2) 104 (13.1)
70 0 9 (1.1)
*KPS data available for 765 and 794 patients treated with pemetrexed plus cisplatin
and pemetrexed plus carboplatin, respectively.
n, number of patients; KPS, Karnofsky performance status.
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Efficacy
In the pemetrexed plus cisplatin group, the overall
response rate for 745 patients evaluable for response was
26.3%, consisting of 15 (2.0%) complete responses and 181
(24.3%) partial responses. In addition, 383 patients (51.4%)
had stable disease as their best tumor response and 139
(18.7%) had progressive disease. In the pemetrexed plus
carboplatin group, the overall response rate for 752 patients
evaluable for response was 21.7%, consisting of 7 (0.9%)
complete responses and 156 (20.7%) partial responses. In
addition, 407 patients (54.1%) had stable disease as their best
response and 158 (21.0%) had progressive disease (Table 2).
The median TTPD in the pemetrexed plus cisplatin
group was 7 months and the median TTPD in the pemetrexed
plus carboplatin group was 6.9 months (Figure 2). The
median overall survival could not be estimated due to the
high censoring rates of 89% for the pemetrexed plus cisplatin
group and 87.1% for the pemetrexed plus carboplatin group.
However, the 1-year survival rate for pemetrexed plus cis-
platin and pemetrexed plus carboplatin was 63.1 and 64.0%,
respectively (Table 3), and Kaplan-Meier survival curves
were estimated (Figure 3).
As per an intent-to-treat analysis, survival was evalu-
ated in all treated patients who received pemetrexed plus
cisplatin (n 843) or pemetrexed plus carboplatin (n 861).
Median survival times and CIs could not be estimated, how-
ever, due to the high censoring rates (84%). However, for
all treated patients, the 1-year survival rate was 60.5% (95%
CI, 50.1–71.0) for the pemetrexed plus cisplatin group and
62.8% (95% CI, 53.5–72.0) for the pemetrexed plus carbo-
platin group. Thus the survival results in treated patients did
not differ considerably from the findings in the efficacy
evaluable populations.
TABLE 2. Best Overall Response Rate in Chemonaïve
Patients with Malignant Pleural Mesothelioma (Evaluable
Patients Only)
Response
Pemetrexed 
Cisplatin
(n  745)
Pemetrexed 
Carboplatin
(n  752)
Complete response, n (%) 15 (2.0) 7 (0.9)
Partial response, n (%) 181 (24.3) 156 (20.7)
Stable disease, n (%) 383 (51.4) 407 (54.1)
Progressive disease, n (%) 139 (18.7) 158 (21.0)
Unknown, n (%) 27 (3.6) 24 (3.2)
Overall response rate, % 26.3 21.7
(95% CI) (23.2, 29.6) (18.8, 24.8)
Disease control rate (responder 
stable disease), %
77.7 75.8
(95% CI) (74.6, 80.7) (72.6, 78.8)
CI, confidence interval; n, number of patients.
TABLE 3. Time to Progressive Disease and Survival in
Chemonaïve Patients with Malignant Pleural Mesothelioma
(Efficacy Evaluable Population)
Event
Pemetrexed 
Cisplatin
(n  745)
Pemetrexed 
Carboplatin
(n  752)
Median TTPD, mo 7.0 6.9
(95% CI) (6.7, 8.3) (6.6, 7.7)
Median survival, mo NA* NA*
(95% CI) (13.4, NA) (12.7, NA)
1-yr survival rate, % 63.1 64.0
(95% CI) (50.7, 75.5) (53.3, 74.6)
Censoring rate, % 89.0 87.1
CI, confidence interval; TTPD, time to progressive disease; n number of patients;
NA, not available.
*Not estimable.
FIGURE 2. Kaplan-Meier analysis of time to progressive disease (months) in chemonaı¨ve evaluable patients with malignant
pleural mesothelioma who received pemetrexed plus cisplatin (n  745) or pemetrexed plus carboplatin (n  752).
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Safety
A total of 843 patients in the pemetrexed plus cisplatin
group and 861 patients in the pemetrexed plus carboplatin
group were qualified for the safety analysis. Only myelosup-
pression data were collected. The CTCAE grade 3 and 4
toxicities observed in each treatment group are summarized
in Table 4. In the pemetrexed plus cisplatin group, the most
commonly reported CTCAE grade 3/4 hematologic toxicities
were neutropenia (23.9%) and leukopenia (13.1%). In the
pemetrexed plus carboplatin group, the most commonly re-
ported CTCAE grade 3 and 4 toxicities were neutropenia
(36.1%), leukopenia (21.0%), anemia (14.3%), and thrombo-
cytopenia (14.3%).
Based on safety data from the Lilly Safety System
database, SAEs for the patient population described in this
manuscript included hematologic events, febrile neutropenia,
nausea, and vomiting. SAEs observed in 1% of the patients
in the pemetrexed plus cisplatin group were nausea (3.3%),
vomiting (2.3%), anemia (1.4%), and neutropenia (1.2%).
SAEs in the pemetrexed plus carboplatin group were anemia
(4.5%), vomiting (3.4%), nausea (2.7%), neutropenia (1.9%),
pancytopenia (1.9%), thrombocytopenia (1.6%), and febrile
neutropenia (1.2%). During the study, a total of seven deaths
were considered by the investigators as possibly related to
study-drug toxicity. Two of these deaths occurred in the
pemetrexed plus cisplatin group (both due to neutropenic
sepsis), and five deaths occurred in the pemetrexed plus
carboplatin group (one each due to septic shock, renal tubular
necrosis, diarrhea, pancytopenia, and neutropenia). During
follow-up, two additional deaths were observed in the pem-
etrexed plus carboplatin group (one each due to circulatory
collapse and septic shock).
DISCUSSION
Pemetrexed-based combinations with platinum analogs
have shown promising activity in patients with MPM (Table
5). This multicenter, nonrandomized, open-label study de-
scribes the largest group of chemonaı¨ve patients reported to
date who were provided access to combination therapy with
pemetrexed plus cisplatin (n  843) or pemetrexed plus
carboplatin (n 861) under the International EAP in Europe.
Of the patients evaluable for the efficacy analysis, the patients
treated with pemetrexed plus cisplatin and pemetrexed plus
carboplatin experienced overall response rates of 26.3 and
21.7%, respectively, with comparable median TTPD (7
months versus 6.9 months) and 1-year survival rates (63.1
versus 64.0%, respectively). Although Kaplan-Meier survival
estimates are presented (Figure 3), these data should be
interpreted with caution given the very high censoring rates
(87–89%). In a similar EAP in the United States, reported
previously by Obasaju et al., chemonaïve patients with MPM
who were treated with the same dosing schedule of pem-
FIGURE 3. Kaplan-Meier analysis of overall survival (months) in chemonaı¨ve evaluable patients with malignant pleural me-
sothelioma who received pemetrexed plus cisplatin (n  745) or pemetrexed plus carboplatin (n  752).
TABLE 4. CTCAE Grade 3/4 Toxicity in Chemonaïve
Patients with Malignant Pleural Mesothelioma (Safety
Population)
Grade 3/4 Toxicity* (%)
Pemetrexed 
Cisplatin
(n  843)†
Pemetrexed 
Carboplatin
(n  861)‡
Neutropenia 23.9 36.1
Leukopenia 13.1 21.0
Anemia 7.2 14.3
Thrombocytopenia 5.0 14.3
*Only myelosuppression data were collected.
†Of 843 patients in the pemetrexed plus cisplatin group, 832 patients had at least
one observation after baseline and 823 patients had at least one observation for
neutrophils.
‡Of 861 patients in the pemetrexed plus carboplatin group, 849 patients had at least
one observation after baseline and 840 patients had at least one observation for
neutrophils.
CTCAE, Common Terminology Criteria for Adverse Events; n, number of patients.
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etrexed plus cisplatin (n  709) demonstrated a response rate
of 20.8% and a 1-year survival rate of 45.9%.6 In the present
study, the overall response rate and 1-year survival rate
observed in European patients was found to be slightly higher
as compared with the U S patients.6 Additionally, the overall
disease control rate was also higher in the present study (77.7
versus 68.3%). We have compared both EAPs to explain the
observed differences in response rates. Regarding the patient
characteristics, the lower median age (62 versus 70 years)
appeared to be in favor of the current International EAP.
In contrast, Vogelzang et al. reported a higher response
rate of approximately 41% in patients treated with pemetrexed
plus cisplatin in their phase III study.4 However, for patients
receiving pemetrexed plus cisplatin, the 1-year survival rate was
somewhat lower in the trial reported by Vogelzang et al.4 than
that observed in this EAP (50.3 versus 63.1%).
The response rates observed in the present study are
within the range of other cisplatin-based combination thera-
pies in MPM. Cisplatin-based combinations with doxorubi-
cin, mitomycin, etoposide, cyclophosphamide, vinblastine,
and raltitrexed resulted in 24 to 26% response rates.19–24 In a
phase III study reported by Vogelzang et al., a higher re-
sponse rate of 41.3% was reported for pemetrexed plus
cisplatin combination therapy.4 The combination of doxoru-
bicin, cisplatin, bleomycin, and mitomycin produced a re-
sponse rate of 44% in one study; however, other investigators
have been unable to reproduce it.25
Other studies similarly demonstrated efficacy with pem-
etrexed plus carboplatin in MPM. Phase I and II trials of
carboplatin in combination with pemetrexed resulted in higher
response rates (19–32%) with prolonged survival (13–15
months) (Table 5).9,10 In this study, the response rate with
pemetrexed plus carboplatin was in the same range (21.7%),
with a 1-year survival rate in a significant number of patients
(64%). Manegold et al. reported on chemonaı¨ve patients in this
EAP who were considered unsuitable for combination chemo-
therapy and therefore received single-agent pemetrexed. Al-
though the overall response rate appeared lower for chemonaïve
patients who received single-agent therapy (10.5%; 95% CI,
7.0–15.0%), it is striking that the 1-year survival rates were
more similar (58.6%, 95% CI, 43.3–73.8%) for patients treated
with single-agent pemetrexed versus 63.1 and 64% (Table 3) for
patients receiving combination therapy.11
In this EAP, the overall response rate, median TTPD,
and 1-year survival rate did not differ considerably between
the two treatment groups. Under the EAP, the first treatment
choice was pemetrexed in combination with cisplatin, thus it
is presumed that patients who received pemetrexed and car-
boplatin in this study were most likely not suitable to receive
the cisplatin-based regimen. The higher median age of 66
years in the pemetrexed plus carboplatin group supports this
argument. It is noteworthy that these patients could tolerate
the carboplatin-based combination very well, as reflected by
a higher median number of treatment cycles.
The hematologic toxicity concurred with the phase III
study of pemetrexed plus cisplatin in MPM,4 and was mod-
erate in both treatment groups. The CTCAE grade 3/4 hema-
tologic toxicities and SAEs appeared to be higher in the
pemetrexed plus carboplatin group. Because this is not a
randomized trial, however, it is unclear to what extent this
difference is linked to carboplatin toxicity or to baseline
differences in the patient groups. Toxic deaths rates were
0.2% for the pemetrexed plus cisplatin group and 0.6% for
the pemetrexed plus carboplatin group.
The results presented here should be interpreted in the
context of the limitations associated with the operation of a
large EAP. Patients were not randomized to treatment groups
and this study was not intended to provide a rigorous com-
parison of pemetrexed plus cisplatin versus pemetexed plus
carboplatin in MPM. Patients treated with pemetrexed plus
carboplatin tended to have poorer clinical status because it
was a secondary treatment option for individuals who likely
could not tolerate cisplatin. In addition, the protocol allowed
physicians to use discretion in evaluating response (Response
Evaluation Criteria in Solid Tumors, Southwest Oncology
Group, and World Health Organization criteria were al-
lowed), which may have resulted in inconsistencies in the
interpretation of individual patient results. Despite these lim-
itations, the findings are significant because they reflect
standard clinical oncology practice. Results are derived from
a large and diverse patient group from multiple countries.
Patient selection was minimal as enrollment criteria were less
TABLE 5. Studies of Combination Chemotherapy with Pemetrexed plus Platinum Analogs in Chemonaïve
Patients with Malignant Pleural Mesothelioma
Authors
Study
Phase
No. of
Patients
Response
Rate (%)
Median
TTPD (mo) Median Survival (mo)
1-yr Survival
Rate (%)
Pemetrexed  cisplatin
Current study EAP 843 26.3 7.0 NE due to high censoring 63.1
Obasaju et al. 20076 EAP 709 20.8 NA 10.9 45.9
Vogelzang et al. 20034 III 226 41.3 5.7 12.1 50.3
Thodtmann et al. 19993 I 11 45.5 NA NA NA
Pemetrexed  carboplatin
Current study EAP 861 21.7 6.9 NE due to high censoring 64.0
Ceresoli et al. 20069 II 102 18.6 6.5 12.7 51.6
Hughes et al. 200210 I 25 32.0 10.2 15.0 NA
TTPD, time to progressive disease; EAP, expanded access program; NE, not estimated; NA, not available.
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stringent than those of a typical randomized trial. Still, the
present International EAP confirmed the activity of pem-
etrexed plus cisplatin, and the hematologic toxicity concurred
with the earlier phase III findings.4 The carboplatin plus
pemetrexed group showed similar efficacy as seen with pem-
etrexed plus cisplatin, and may be a possible choice for patients
who are not suitable for cisplatin-based chemotherapy.
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